Citalopram updated on 07-01-2025

Low Apgar score (< 7) (at 1 min)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18431
R78047		 Lee (Controls exposed to TCAs), 2025 1-minute Apgar score <7 during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 2.13 [0.98;4.62] C
excluded (control group) 		9/81   34/613 43 81
ref
S18412
R77784		 Lee (Controls unexposed, general pop), 2025 1-minute Apgar score <7 during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 2.58 [1.28;5.20] 9/81   14,883/463,440 14,892 81
ref
S7696
R22821		 Kivistö, 2016 Low (<7) Apgar score at 1 min during pregnancy (anytime or not specified) retrospective cohort unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 2.60 [1.73;3.91] -/215   1,451/24,402 - 215
ref
Total 2 studies 2.59 [1.82;3.69] 14,892 296
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Lee (Controls unexposed, general pop), 2025Lee, 2025 1 2.58[1.28; 5.20]14,8928125%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Kivistö, 2016Kivistö, 2016 2.60[1.73; 3.91]-21575%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 2.59[1.82; 3.69]14,8922960.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, general pop;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.59[1.82; 3.69]14,8922960%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.59[1.82; 3.69]14,8922960%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 Tags Adjustment   - Yes  - Yes 2.59[1.82; 3.69]14,8922960%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 2.59[1.82; 3.69]14,8922960%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 All studiesAll studies 2.59[1.82; 3.69]14,8922960%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18431

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.59[1.82; 3.69]16,3342960%NALee (Controls unexposed, general pop), 2025 Kivistö, 2016 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.13[0.98; 4.62]4381 -NALee (Controls exposed to TCAs), 2025 10.510.01.0